Kodiak Sciences (NASDAQ:KOD - Get Free Report)'s stock had its "neutral" rating restated by investment analysts at Chardan Capital in a report released on Monday,Benzinga reports. They presently have a $14.00 target price on the stock. Chardan Capital's price target would suggest a potential downside of 9.43% from the stock's previous close.
A number of other equities analysts have also recently issued reports on the stock. Wall Street Zen upgraded shares of Kodiak Sciences from a "sell" rating to a "hold" rating in a research note on Friday, September 26th. JPMorgan Chase & Co. raised shares of Kodiak Sciences from an "underweight" rating to a "neutral" rating and set a $15.00 price target for the company in a report on Thursday, August 14th. Barclays raised shares of Kodiak Sciences from an "underweight" rating to an "equal weight" rating and increased their price objective for the stock from $7.00 to $17.00 in a report on Thursday, September 25th. HC Wainwright increased their price objective on shares of Kodiak Sciences from $3.00 to $5.00 and gave the stock a "neutral" rating in a report on Monday, August 18th. Finally, Jefferies Financial Group assumed coverage on shares of Kodiak Sciences in a report on Monday, September 22nd. They set a "buy" rating and a $15.00 price objective on the stock. One investment analyst has rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Kodiak Sciences currently has a consensus rating of "Hold" and a consensus target price of $13.20.
Read Our Latest Analysis on Kodiak Sciences
Kodiak Sciences Stock Performance
Shares of Kodiak Sciences stock traded up $0.40 during midday trading on Monday, reaching $15.46. 49,194 shares of the company's stock traded hands, compared to its average volume of 514,194. Kodiak Sciences has a 52 week low of $1.92 and a 52 week high of $19.39. The company's 50 day simple moving average is $10.24 and its 200 day simple moving average is $6.04. The company has a market cap of $816.49 million, a price-to-earnings ratio of -4.06 and a beta of 2.67.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.01) by ($0.02). As a group, equities research analysts predict that Kodiak Sciences will post -3.45 earnings per share for the current year.
Institutional Investors Weigh In On Kodiak Sciences
Several hedge funds have recently bought and sold shares of KOD. Adage Capital Partners GP L.L.C. lifted its position in Kodiak Sciences by 55.1% during the second quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company's stock valued at $7,668,000 after purchasing an additional 730,000 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Kodiak Sciences by 27.0% in the first quarter. Acadian Asset Management LLC now owns 1,946,134 shares of the company's stock worth $5,454,000 after acquiring an additional 413,821 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Kodiak Sciences by 90.1% in the first quarter. Jacobs Levy Equity Management Inc. now owns 685,198 shares of the company's stock worth $1,922,000 after acquiring an additional 324,722 shares during the last quarter. Nantahala Capital Management LLC lifted its holdings in shares of Kodiak Sciences by 99.1% during the first quarter. Nantahala Capital Management LLC now owns 530,713 shares of the company's stock valued at $1,489,000 after purchasing an additional 264,100 shares in the last quarter. Finally, ICONIQ Capital LLC lifted its holdings in shares of Kodiak Sciences by 24.6% during the first quarter. ICONIQ Capital LLC now owns 1,266,563 shares of the company's stock valued at $3,559,000 after purchasing an additional 249,699 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.
Kodiak Sciences Company Profile
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
